Utah People's Post

The Latest News from the Beehive State

Monday, January 18, 2021
Log in
  • National News
    • Female Caseworker Killed & Doctor Shot in Philadelphia
  • State News
    • Car Chase Leads to Drug Arrest
  • Tech & Science
  • Health
    • How to Prepare For Ticks Season
    • Magical Weight Loss Bean Scam
  • Sports
  • Business
You are here: Home / Health / New Drug Improves Vision In Clinical Trial for Macular Edema

New Drug Improves Vision In Clinical Trial for Macular Edema

Posted by

retina

Researchers say that the drug Eylea is more efficient than Avastin during the first year of treatment. Patients with diabetic macular edema had better vision gains following the new prescription after a two-year clinical trial.

In patients suffering from mild vision loss, Eylea was found to be as efficient as other drugs on the market for DME, but the potential adverse effects now offer doctors a safer alternative.

DME is a side effect of diabetes and involves the blurring of the macula, the part of the retina we use for central vision. This blurring is caused by blood vessels leaking fluid from into the retina.

One of the treatments for this progressive disease involves injecting a drug into the eye, which prohibits the production of the vascular endothelial growth factor, a substance that contributes to the abnormal blood vessel growth and the consequent leakage.

According to a recent estimate, roughly 750,000 of the 7.7 million people in the U.S. living with diabetic retinopathy also suffer from DME. Last year, the Food and Drug Administration had approved Eylea for use in DME patients.

Dr. John Wells, a retinal specialist working with the Palmetto Retina Center, said in a press release that this study suggests just a small advantage of choosing Eylea over Avasting when it comes to patients who have mild visual loss caused by macular edema.

However, when the patient’s visual acuity dropped from 20/40 to 20/50 or worse, the Eylea drug turned to have greater benefits, as it outperformed Avastin and Lucentis in the two-year study.

For the trial, researchers with the National Institutes of Health enrolled 660 DME patients at 89 sites in the U.S., who averaged at 61 years old. All of the patients had been diagnosed with Type 1 or Type 2 diabetes for at least a year.

The results, which are featured in the journal Ophthalmology, were based on the patients being randomly treated with Eylea, Lucentis or Avastin for two years.

Among the patients with initial with 20/40 vision, the improvement was roughly the same – averaging at 20/25. However, when the patients started out with 20/50 vision or worse at the onset of the trial, the vision was found to improve significantly over the course of two years.

After the first year of the study, Eylea patients reported better results; however, on the long-term, the three drugs seemed to have similar results, which means doctors can opt for the one they think its best for a patient’s condition.
Image Source: Ingalls Health System

Share this:

  • Tweet
  • Share on Tumblr
  • Email

Filed Under: Health

mm

About Gabrielle Stewart

Gabrielle Stewart graduated from Case Western Reserve University’s School of Graduate Studies with a Masters of Arts in Communication Sciences. She’s an avid reader and a lifelong learner. She likes to cover a wide range of news, but she’s particularly keen on Science.

Woman working out at the gym

Just 23% of Americans Are Working Out Enough in Their Spare Time

By

Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

By

United Airlines airplane

Passenger Mysteriously Dies on United Airlines flight Bound for Boston

By

Breakfast sandwich

Here Are Some Foods No Nutritionist Would Ever Eat

By

Poppy flower

UN Warns of Surge in Opium-based Drugs and Cocaine Supply

By

U.S.-Canada border

French Jogger Detained 2 Weeks for Accidentally Crossing Border

By

Plus size model

Normalizing Plus Size Could Fuel Obesity Crisis (Study)

By

Giant manta ray

Unique Manta Ray Nursery Spotted off Texas Coast

By

The rainbow flag

WHO Scraps Transgenderism from List of Mental Illnesses

By

456 People Dead at U.K. Hospital after Taking too Many Painkillers

By

Kenyan girls dancing

Kenyans Facing Poor Nutrition as Supermarket Shopping Is on the Rise

By

Pages

  • About
  • Contact
  • Privacy Policy GDPR
  • Staff
  • Terms and Conditions

Recent Posts

  • Just 23% of Americans Are Working Out Enough in Their Spare Time
  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)
  • Passenger Mysteriously Dies on United Airlines flight Bound for Boston
  • Here Are Some Foods No Nutritionist Would Ever Eat
  • UN Warns of Surge in Opium-based Drugs and Cocaine Supply
  • French Jogger Detained 2 Weeks for Accidentally Crossing Border
  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

Related Articles

  • Woman working out at the gym

    Just 23% of Americans Are Working Out Enough in Their Spare Time

  • Poliovirus Therapy Gives Brain Cancer Patients New Hope (Study)

  • Breakfast sandwich

    Here Are Some Foods No Nutritionist Would Ever Eat

  • Normalizing Plus Size Could Fuel Obesity Crisis (Study)

  • The rainbow flag

    WHO Scraps Transgenderism from List of Mental Illnesses

  • 456 People Dead at U.K. Hospital after Taking too Many Painkillers

  • Young woman affected by depression

    If You Have PTSD You Were Likely Abused as a Child

  • Obese dog on a leash

    Obese Dogs Can Help Us Better Understand How Obesity Works

  • Our Brains Are Craving Combinations of Fats and Carbs (Study)

  • Hungry bird with beck open

    Scientists Explain Why We Get ‘Hangry’

Categories

  • Business
  • Entertainment
  • Health
  • National News
  • Nature
  • Provo
  • Salt Lake News
  • Science
  • Sports
  • State News
  • Tech & Science
  • Technology
  • Uncategorized
  • West Jordan
  • West Valley City
  • World

Copyright © 2021 utahpeoplespost.com

About · Privacy Policy · Terms of Use · Site Map · Contact

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This website uses cookies to ensure you get the best experience on our website. Learn more.